PDMS-based systems are often used as micellar carriers of anti-cancer substances (e.g., doxorubicin) [31], nanoparticles (e.g., with cathepsin B, lysosomal cysteine proteases that associate with premalignant lesions and invasive stages of cancer) [32], and PDMS-modified silica xerogels with Ag nanoparticles (progesterone delivery) [33]. The gene discussed is CTSB; the disease is cancer.